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BACKGROUND: Both irinotecan (CPT-11) and S-1 are active against colorectal cancer; however, as S-1 is a prodrug of 5-fluorouracil
(5-FU), 5-FU and its metabolites might inhibit the antitumour effect of CPT-11. Therefore, we designed a sequential combination, in
which CPT-11 infusion was given on day 1 and S-1 was given orally at 80mgm
 2 per day on days 3–16 every 3 weeks.
METHODS: Twelve patients entered the phase I study, and the recommended doses were determined as a CPT-11 dose of
150mgm
 2 and an S-1 dose of 80mgm
 2.
RESULTS: In all, 36 patients entered the phase II study, of whom 4 and 16 had complete and partial responses. The overall response
rate was 55.6% (95% confidence interval, 38.1–72.1%), and median progression-free survival was 7.7 months (95% confidence
interval, 4.8–12.6 months). Grade 3 neutropenia was the most common haematological toxicity and occurred in 6.5% of 215
treatment courses. Grade 3 non-haematological toxicities included anorexia (1.4%) and diarrhoea (0.9%). There was no grade 4
toxicity of any kind.
CONCLUSION: Our results suggest that this regimen is convenient, safe and promising, compared with conventional regimens for
patients with metastatic colorectal cancer.
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The development of new cytotoxic and molecular targeting agents
has improved survival in patients with metastatic colorectal cancer
(Douillard et al, 2000; Saltz et al, 2000; de Gramont et al, 2000;
Cunningham et al, 2004; Hurwitz et al, 2004; Thirion et al, 2004).
One of them is irinotecan (CPT-11), a potent inhibitor of
topoisomerase I (Kawato et al, 1991; Pitot et al, 1997), which is
combined with intravenous bolus 5-fluorouracil (5-FU) and
leucovorin (LV) in the IFL regimen (Saltz et al, 2000) or with
continuous intravenous infusion of 5-FU in the FOLFIRI regimen
(Douillard et al, 2000). Two randomised phase III trials relating to
IFL and FOLFIRI have shown survival benefits with a median
overall survival time (MST) of 14.8–17.4 months (Douillard et al,
2000; Saltz et al, 2000). Recent reports have shown that FOLFIRI
seems to be better tolerated (Benson and Goldberg, 2003), with less
frequent toxicities such as diarrhoea, myelosuppression and
infection than IFL; however, FOLFIRI needs an indwelling central
venous catheter and a portable pump. Its usage is therefore
complex and can cause problematic complications such as infection
and thrombosis (Groeger et al, 1993; Verso and Agnelli, 2003).
S-1 is a new oral fluoropyrimidine developed by Taiho
Pharmaceutical Co., Ltd (Tokyo, Japan), and is based on the
biochemical modulation of 5-FU. This drug contains tegafur (FT),
gimeracil (5-chloro-2,4-dihydoroxypyridine; CDHP) and oteracil
(potassium oxonate; Oxo) at a molar ratio of 1:0.4:1 (Shirasaka
et al, 1996a). FT, a prodrug of 5-FU, is absorbed well after oral
ingestion and is converted to 5-FU mainly in the liver and tumour
cells. CDHP, a strong inhibitor of dihydroxypyrimidine dehydro-
genase, suppresses the degradation of 5-FU and maintains high
5-FU concentrations in the blood for long periods of time (Tatsumi
et al, 1987; Shirasaka et al, 1996b). Oxo, which inhibits orotate
pyrimidine phosporibosyl transferase, decreases the levels of
5-fluorouridine 50-monophosphase and 5-FU incorporated into
RNA only in the small intestine, and remains in the digestive tract
after oral administration, reducing the gastrointestinal toxicity of
5-FU (Shirasaka et al, 1993).
Several phase II studies of S-1 monotherapy have shown that
response rates ranged from 19 to 39%, and S-1 seemed to be a
promising agent in patients with advanced colorectal cancer
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s(Ohtsu et al, 2000; Van den Brande et al, 2003; Shirao et al, 2004).
Combining CPT-11 with oral S-1 is compelling because the agents
have different modes of action and home-based administration of
oral S-1 is safe and convenient, compared with FOLFIRI. However,
it has been shown that 5-FU or its metabolites may inhibit the
activity of carboxylesterase, which converts CPT-11 to SN-38
(7-etyl-10-hydroxycamptothecin), a major active metabolite of CPT-
11, from pharmacokinetic data (Sasaki et al, 1994; Falcone et al,
2001). If CPT-11 and S-1 are administrated simultaneously, S-1, a
prodrug of 5FU, might inhibit the anti-tumour activity of CPT-11.
We therefore designed sequential therapy in which CPT-11 on
day 1 and S-1 on days 3–16 were administered every 3 weeks, and
conducted a phase I/II study of this regimen.
MATERIALS AND METHODS
Patients
The objectives of this study were to determine the maximum
tolerated dose (MTD) and the recommended dose (RD), and to
evaluate the toxicity and efficacy of the above sequential
combination.
All patients had to have histologically confirmed colorectal cancer
with measurable or evaluable lesions on the basis of the Response
Evaluation Criteria in Solid Tumors Group (RECIST) criteria
(Therasse et al, 2000). Previous chemotherapy regimen had to be
one or less, but not including CPT-11 or S-1, and previous
chemotherapy or radiotherapy had to have been completed at least
4 weeks before entry. Other eligibility criteria included an Eastern
Clinical Oncology Group (ECOG) scale performance status of 2 or
less; age between 20 and 75 years; the ability to ingest S-1 orally; life
expectancy of at least 3 months; provision of written informed
consent in accordance with government and institutional guidelines;
adequate organ function defined by a WBC count from 4000 to
12000 per mm
2; an absolute neutrophil count of X2000 per mm
2;a
haemoglobin value of X9.0gdl
 1; a platelet count of X10 10
4 per
mm
2; AST and ALT levels within two times the normal upper limit or
150IUdl
 1 in the presence of liver metastasis; total bilirubin
p1.5mgdl
 1; and serum creatinine within the normal limits of
each institute and/or creatinine clearance of X50mlmin
 1 by the
calculation of Cockcraft–Gault. Exclusion criteria included active
infection; diarrhoea (watery stools); severe pleural effusion or ascites;
symptoms attributable to brain metastasis; serious complications
such as intestinal paralysis, intestinal obstruction, interstitial
pneumonia or pulmonary fibrosis; concomitant uncontrolled, non-
malignant disease such as hypertension or cardiac, pulmonary, renal
or hepatic disease; synchronous double cancer; a previous history of
treatment for psychiatric diseases; pregnancy, possible pregnancy or
lactation; a history of drug sensitivity to CPT-11 or S-1; flucytosin
treatment; or judged ineligible for this protocol by the attending
physician. The protocols were approved by the ethics committees of
our institutions.
Treatment regimens
CPT-11 was administrated as a 90-min intravenous infusion on
day 1 and S-1 was administrated orally at 40mgm
 2 twice daily
(i.e., 80mgm
 2 per day) within 1h after breakfast and supper on
days 3–16 every 3 weeks. The doses of S-1 were assigned on the
basis of body surface area (BSA) as follows: BSA o 1.25m
2,8 0m g
per day; 1.25m
2 p BSA o 1.5m
2, 100mg per day; 1.5m
2 p BSA,
120mg per day.
In the phase I study, the dose escalation of CPT-11 was
conducted with a fixed S-1 dose of 80mgm
 2 per day. Four
escalating dose levels of CPT-11 were prepared (Table 1). Level 1
was the starting dosage level but level 0 was also prepared, because
level 1 might have been the MTD. The level 3 dose of CPT-11 was
based on the upper limit recommended by the Japanese
Government Health Care Insurance Organization. All toxicities
were graded according to the Japanese version of the National
Cancer Institute Common Toxicity Criteria (NCI-CTC v3.0) (JCOG
and JSCO, 2004). DLT was defined as follows: (1) grade 4
leucocytopaenia; (2) grade 4 neutropaenia; (3) grade 3 febrile
neutropaenia for 3 days or more; (4) grade 4 thrombocytopaenia
or anaemia; (5) grade 3 or 4 non-haematological toxicity except
alopaecia; (6) delay of more than 14 days in initiating the second
cycle of therapy. To determine the MTD, only DLTs occurring
during the first cycle of therapy were considered. At least three
patients were entered at each level. If one patient at a certain dose
level experienced DLT, then three additional patients were treated
at the same dose level. Dose escalation was not allowed in
individual patients. MTD was defined as the dose level that
resulted in at least two of six patients developing DLTs. The RD of
the phase II study was to be the dose immediately below the MTD.
If MTD was not reached, the level 3 dosage was considered to be
the RD.
In the phase II study, the dosage of CPT-11 was the RD, and
eligibility and exclusion criteria were the same as those for the
phase I study. The eligibility criteria of subsequent courses
included the following: a WBC count of X3000 per mm
2;a
neutrophil count of X1500 per mm
2; a platelet count of X10 10
4
per mm
2; serum creatinine within the normal limits of each
institute; total bilirubin p1.5mgdl
 1; grade 1 or less non-
haematological toxicity, except any alopaecia and pigmentation;
no watery diarrhoea; and no infection causing fever of more than
381C. If eligibility criteria were not met by day 35 of a given course,
the patient was excluded from further study. If previous treatment
courses were delayed or interrupted because of toxicity, the dose of
CPT-11 was reduced to one level lower for subsequent courses, but
the dosage of S-1 was not changed. If a further reduction of CPT-11
was needed, the patient was excluded from the study. If S-1 was
interrupted within a course because of toxicity and the subsequent
course could not be started within less than 14 days from the
interruption of S-1, the patient was also excluded from this study.
Once lowered, the dose of CPT-11 could not be increased.
Symptomatic treatment was given as required. A 5-hydroxy-
tryptamine-3 receptor antagonist and dexamethasone were given
to all patients in a 30-min infusion before the administration of
CPT-11. The use of granulocyte colony-stimulating factors (GCS-F)
was allowed if necessary. If possible, intestinal alkalisation by the
intake of more than 1000ml per day of alkaline water and/or 1.8g
per day of sodium bicarbonate and control of defecation with 2.0g
per day of magnesium oxide for 4 days after the administration of
CPT-11 were performed to prevent delayed diarrhoea after CPT-11.
Response evaluation and toxicity
Pretreatment evaluation included complete patient histories,
physical examinations, complete blood cell counts, biochemistry
involving liver and renal functions, urinalysis, tumour markers
(CEA, CA19–9, etc.), chest roentgenogram, electrocardiogram and
computed tomographic scans of the abdomen and chest. Accord-
ing to NCI-CTC version 3.0 (JCOG and JSCO, 2004), toxicity and
laboratory variables in complete blood cell counts, biochemistry
and urinalysis were assessed weekly during the first course, on
Table 1 Phase I dose escalation
Dosage level
CPT-11
(mgm
 2)
TS-1
(mgm
 2)
No. of enroled
patients
07 5 8 0 0
1 100 80 3
2 125 80 6
3 150 80 3
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sdays 1 and 15 from the second through to the sixth course and at
least once during subsequent courses. CT scans were repeated to
evaluate lesions every two courses, and tumour markers were
measured at the same time. Responses were evaluated according to
the RECIST criteria (Therasse et al, 2000). Complete and partial
responses required subsequent confirmation of response after an
interval of at least 4 weeks.
Statistical considerations
The phase II study was designed to test the null hypothesis that the
true response probability is not less than the clinically significant
level of 25%. The response rate of first-line FOLFIRI was 50%. The
response rate of this study was expected to be 45%, because it was
probable that patients had previously received some regimens of
chemotherapy. The probability of accepting treatment with a
response probability (25%) was P¼0.05. The probability of
rejecting treatment with a response rate (45%) was P¼0.2;
therefore, the required number of patients was estimated to be 32.
We planned to evaluate toxicity and efficacy after enroling 16
patients. Had this regimen been toxic or had there been fewer than
four patients with a response, this study would have been halted.
In the phase II study, survival was calculated from treatment
initiation data by the Kaplan–Meier method.
RESULTS
Patient characteristics
We enroled 12 patients in the phase I study between March 2005
and January 2006 (Table 2). All 12 patients were evaluated for
toxicity and had evaluable lesions for response. The median age of
patients was 55.5 years (range, 37–71), nine had an ECOG PS of 0
and three had an ECOG PS of 1. The primary lesions were in the
colon in seven patients and in the rectum in five patients, and 10
primary lesions were resected. The metastatic sites were the lung in
two patients, liver in six, lymph nodes in nine and peritoneum in
one. Nine patients had received chemotherapy earlier with bolus
5-FU and LV regimen, and three patients were chemotherapy naive.
In the phase II study, all 36 patients enroled between February
2005 and February 2008 met all eligibility requirements and
received at least one course of treatment. Patient characteristics are
summarised in Table 2, and all patients were evaluated for toxicity
and response. The median age of patients was 58.5 years (range,
21–73 years); 30 patients had an ECOG PS of 0 and 6 patients had
an ECOG PS of 1. Primary sites were the colon in 21 patients and
the rectum in 15 patients, and 9 primary lesions were resected.
Metastatic sites were the lung in 11 patients, liver in 20, lymph
nodes in 12, intrapelvic cavity in 8, peritoneum in 5, pleura in 1,
ovary in 2 and spleen in 1. Five patients had received
chemotherapy earlier with bolus 5-FU and LV regimen, and 31
patients were chemotherapy naive.
Determination of MTD in the phase I study
In the phase I study, all patients were evaluable for adverse
reactions and completed one or more cycles of treatment. At level
2, one patient exhibited grade 3 ileus on day 20 of the first cycle,
but no other DLT occurred in phase I. The MTD was not reached,
and we determined that the level 3 dosage was the RD, which was a
CPT-11 dose of 150mgm
 2 with an S-1 dose of 80mgm
 2.
Adverse reactions in the phase I study are summarised in Table 3.
Safety
All 36 patients enroled in the phase II study were assessable for
safety, and received 215 treatment courses (median, 5 courses;
range, 1–20 courses). In these 36 patients and 215 courses,
treatment delay within 2 weeks, dose reduction or both occurred in
8, 3 and 2 patients and 45, 5 and 2 courses, respectively. All
treatment delays were due to delays in recovery of neutropaenia,
and dose reductions were due to grade 3 anorexia and general
fatigue. Four patients refused to continue treatment after one
Table 2 Patient characteristics
Phase I (n¼12) Phase II (n¼36)
Median age, years (range) 55.5 (37–71) 58.5 (21–73)
Male/female 9/3 16/20
ECOG performance score
09 3 0
13 6
Primary lesions
Colon 7 21
Rectum 5 15
Histological differentiation
Well 5 9
Moderately 5 20
Poor 2 7
Primary site
Yes 2 9
No 10 27
Sites of metastasis
Liver 6 20
Lung 2 11
Lymph node 9 12
Peritoneum 1 5
Pelvic cavity 0 8
Ovary 0 2
Pleura 0 1
Spleen 0 1
Prior chemotherapy
Yes 9 6
No 3 30
Abbreviation: ECOG¼Eastern Clinical Oncology Group.
Table 3 Adverse reactions during the first cycle in phase I
Dosage level
1( n¼3) 2 (n¼6) 3 (n¼3)
Grade of toxicity 123412341234
Haematological
Leucopaenia 0 00011001000
Neutropaenia 2 00001000000
Anaemia 0 10010000000
Non-haematological
Anorexia 1 20002000000
Nausea 1 00041001000
Diarrhoea 1 00011002000
Stomatitis 0 00000001000
Constipation 1 10000000000
Ileus 0 00000100000
Fever 1 00010000000
General fatigue 0 10010000000
Rash 0 00001000000
Alopecia 2 00040001000
DLT 0 1 0
Abbreviation: DLT¼dose limiting toxicity.
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scourse because of obstruction of the gastrointestinal tract, skin
rash, anorexia or stomatitis.
The overall incidences (%) of haematological and non-
haematological toxicities in the phase II study are listed in Table 4.
Grade 3 neutropaenia was the most common adverse event and
occurred in 6.5% of the 215 treatment courses, but GCS-F was not
used. No patient had febrile neutropaenia. Major non-haematolo-
gical toxicities were liver dysfunction, anorexia, stomatitis,
diarrhoea and alopecia. Grade 3 non-haematological toxicities
were anorexia (1.4%), diarrhoea (0.9%), nausea (0.5%), vomiting
(0.5%), ileus (0.5%) and general fatigue (0.5%). There were no
serious unexpected adverse events and no treatment-related
deaths.
Efficacy
In the phase I study, all patients had lesions that could be evaluable
for response, but one patient was not evaluable (NE) because the
protocol was discontinued due to DLT. Patients included one with
CR, four with PR, four with SD and two with PD, yielding a
response rate of 41.7% (Table 5).
In the phase II study, all 36 patients had at least one measurable
lesion. Response data are shown in Table 5. The overall response
rate was 55.6% (95% confidence interval, 38.1–72.1%); 4 patients
had CR, 16 had PR, 6 had SD, 6 had PD and 4 were defined as NE.
Two of four patients with CR had had lymph node metastases, one
had had liver metastases and one had had intrapelvic masses.
Subgroup analysis based on previous chemotherapy showed that
the response rate was 58.1% (18 out of 31) among those who had
not undergone chemotherapy earlier and 40% (two out of five)
among those who had undergone chemotherapy earlier. At a
median follow-up time of 12 months, the median progression-free
survival (PFS) time was 7.7 months (range, 1.2–19.9þmonths;
95% confidential interval, 4.8–12.6 months) (Figure 1). As survival
times in more than half of the patients were not yet evaluable, the
MST could not be calculated.
DISCUSSION
This study determined the MTD and RD, and also evaluated the
toxicity and efficacy of the sequential combination of CPT-11 and
S-1 in patients with metastatic colorectal cancer. As there was only
one DLT, and the RD was 150mgm
 2 and 80mgm
 2 of CPT-11
and S-1, respectively, MTD could not be determined. Our phase II
results showed that CPT-11 and S-1 were very effective, with a
response rate of 55.6% and a median PFS of 7.2 months. These
results are comparable with those of FOLFIRI (Douillard et al,
2000), and this combination might therefore be considered as a
substitute of FOLFIRI, especially because of the lower toxicity.
Toxicity was very mild and the number of adverse events was
very small. There were no grade 4 adverse events, and although the
most common grade 3 adverse effect was neutropaenia, its
incidence was only 6.5%. GCS-F did not have to be used and no
febrile neutropaenia occurred. No severe non-haematological
toxicities occurred, and the incidence of grade 3 non-haematolo-
gical toxicities was also very low. This shows that our regimen is
very safe and manageable on an outpatient basis.
Goto et al (2006) reported another regimen of CPT-11 combined
with S-1 in patients with advanced colorectal cancer. In their
regimen, CPT-11 was given on day 1 and S-1 on days 1–14,
repeated every 3 weeks. Their response rate was 62.5% and the
Table 4 Adverse reactions in all phase II 215 treatment courses
Grade of toxicity
All grades
(%)
Grades 3
and 4 (%) Toxicity (n¼215) 1 2 3 4
Haematological
Leucopaenia 5 41 3 0 22.8 1.4
Neutropaenia 11 50 14 0 34.9 6.5
Anaemia 15 29 2 0 21.4 0.9
Non-haematological
Anorexia 12 14 3 0 13.5 1.4
Nausea 11 8 1 0 9.3 0.5
Vomiting 13 4 1 0 8.4 0.5
Diarrhoea 18 20 2 0 18.6 0.9
Stomatitis 19 3 0 0 10.2 0
Constipation 1 0 0 0 0.5 0
Ileus 0 0 1 0 0.5 0.5
Fever 1 0 0 0 0.5 0
General fatigue 6 6 1 0 6.1 0.5
Rash 0 3 0 0 1.4 0
Tearing 3 3 0 0 2.8 0
Alopecia 139 0 0 0 64.7 0
Bilirubin 20 4 0 0 11.2 0
GOT 40 1 0 0 19.1 0
GPT 35 3 0 0 17.7 0
Table 5 Overall response
No. of
patients CR PR SD PD NE
Response
rate (%)
Phase I
Overall 12 1 4 4 2 1 41.7
Level
1 3 0 1 1 1 0 33.3
2 6 0 2 2 1 1 33.3
3 3 1 1 1 0 0 66.7
Phase II
Overall 36 4 16 6 6 4 55.6
Prior chemotherapy
No 31 4 14 5 4 4 58.1
YES 5 0 2 1 2 0 40
Abbreviation: NE¼not evaluable.
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Figure 1 Progression-free survival time of 36 patients with metastatic
colorectal cancer who received sequential therapy with irinotecan and S-1
in the phase II study. The median progression-free survival was 7.7 months
(95% confidence interval, 4.8–12.6 months).
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smedian PFS was 8.0 months; however, all patients in their study
were chemotherapy naive, whereas 5 of 36 pretreated patients were
involved in our study. As subgroup analysis on the basis of earlier
chemotherapy showed that the response rate was 58.1% (18 of 31)
among patients who had not undergone previous chemotherapy in
our study, it is difficult to make a simple comparison between their
study and ours. In terms of the overall number of all grades of
adverse effects, their regimen seemed to have more adverse effects
than ours, but figures for the numbers of grade 3 or more were
similar in both regimens. As the two regimens could not be fully
compared, as there was no randomised trial, we could not identify
the superior regimen.
Capecitabine is another oral fluoropyrimidine derivative. Patt
et al (2007) conducted a phase II study of capecitabine plus
3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy
for metastatic colorectal cancer. Their response rate was 50% and
median PFS was 7.8 months; however, the incidence and degree of
adverse events were high: grade 3/4 neutropaenia (25%), diarrhoea
(20%), vomiting (16%), dehydration (10%), nausea (6%), abdom-
inal pain (6%) and hand–foot syndrome (6%); most patients
(94%) required a dose reduction of either CPT-11 or capecitabine
or both. In our study, the toxicity profile was lower, with treatment
delay and/or dose reduction occurring in only 25% of all treatment
courses, and suggesting that S-1 is superior to capecitabine as an
oral partner of CPT-11.
Oral uracil/tegafur (UFT) with oral LV was also combined with
CPT-11. Mackay et al (2003) conducted a phase I/II trial of UFT,
LV and CPT-11 inpatients with advanced colorectal cancer. Their
response rate was 19%, whereas 35% of patients at the RD level
needed dose reductions because of grade 3/4 neutropaenia and
grade 3 diarrhoea. Taken together, these results suggest that CPT-
11 and S-1 are safer and more active than UFT, LV and CPT-11 in
patients with metastatic colorectal cancer.
The incidence of diarrhoea was very low in our study, with grade
3 diarrhoea occurring in only 0.9% of all courses. CPT-11 is
hydrolysed by hepatic carboxylesterase to create 7-ethyl-10-
hydroxy-camptothecin (SN-38), and a portion of SN-38 undergoes
subsequent conjugation by UDP-glucuronyltransferase to form
inactive SN-38-glucuronide (SN38-Glu) in the liver. CPT-11, SN-38
and SN38-Glu are mainly excreted into bile and discharged into
stool, but some amount is reabsorbed into the enterohepatic
circulation to a certain extent by intestinal cells. Enterocolitis
caused by high levels of SN-38 and/or CPT-11 retained for long
periods of time in the small intestine is thought to be the direct
cause of diarrhoea associated with CPT-11 (Ikegami et al, 2002;
Alimonti et al, 2004). It is thought that oral alkalisation combined
with control of defecation could prevent CPT-11-induced diar-
rhoea (Takeda et al, 2001; Alimonti et al, 2004). In our study, oral
alkalisation and control of defecation were performed as much as
possible, and might be the reason for the low incidence of
diarrhoea.
In conclusion, our results showed that the RD of CPT-11 and S-1
in our regimen was 150mgm
 2 and 80mgm
 2, respectively, and
sequential therapy with CPT-11 and S-1 is safe and effective
compared with conventional regimens in patients with advanced
colorectal cancer. This promising regimen might be an alternative
to FOLFIRI. A randomised control study comparing FOLFILI and
our protocol regimen with or without molecular targeting agents is
warranted.
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